Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223951 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
A Phase 3 study of Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis, sponsored by Vistakon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
- 6
- Study locations
NCT00223951: Completed Phase 3 study of Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis, sponsored by Vistakon Pharmaceuticals.
NCT00223951 is a Phase 3 study of Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 900 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00223951, a Phase 3 study of Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis, has completed, sponsored by Vistakon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers
Conditions Studied
Interventions
- DRUG R89674 (generic name not yet established)
Study Locations (6)
Arizona
- - Phoenix
Maryland
- - Bel Air
Massachusetts
- - North Andover
Nevada
- - Las Vegas
North Carolina
- - Charlotte
Pennsylvania
- - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2005-09 |
| Phase | Phase 3 |
What the finished NCT00223951 record still lists
NCT00223951 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis appearing as the primary indexed condition, and to 1 intervention - of which R89674 (generic name not yet established) is the first listed.
NCT00223951 lists 6 locations in 6 states (Arizona, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00223951 about?
NCT00223951 is a clinical study titled "Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers". The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers
What is the current status of trial NCT00223951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2005-09.
What conditions does trial NCT00223951 study?
This clinical trial studies the following conditions: Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis.
What interventions are being tested in trial NCT00223951?
The interventions under investigation include: R89674 (generic name not yet established) (DRUG).
Who is sponsoring clinical trial NCT00223951?
This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00223951 being conducted?
This trial has 6 study locations across Arizona, Maryland, Massachusetts, Nevada, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00223951's enrollment target sits among peer trials
900 350th of 2000 higher than 1,641 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia